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The isoquinoline carboxamide derivative PH]PKl1195, a ligand for the peripheral-type benzodiazepine (BZD) receptor, 
binds to Chinese hamster ovary (CHO) cell mitochondria in a specific and saturable manner. Scatchard analysis showed 
the presence of a single-binding site with an apparent dissociation constant (&) of 12.0* 1 .O nM and a maximal binding 
capacity of 23.0* 2.0 pmol/mg protein. The pharmacological characterization of this CHO BZD-binding site, based on 
the displacement of PHlPK11195 by several drugs of known binding specificity, indicated that it is of the peripheral-type. 
The photoaffinity probe PHlPKl4105, a nitrophenyl derivative of PHlPKl1195, specifically labeled a 17 kDa CHO mito- 
chondrial protein. This 17 kDa protein was purified from digitonin-solubilized mitochondria by gel-filtration chroma- 
tography and two reverse-phase HPLC steps. The purified material migrated as a single band on silver stained or auto- 
radiographed SDS-polyacrylamide gels, and had an amino acid composition corresponding to a 17 kDa protein rich in 
Leu, Val, Ala, Gly, and Pro. Analysis of the amino-terminal sequence of the purified 17 kDa protein revealed a blocked 
amino-terminus. 
Benzodiazepine; Receptor; Purification; HPLC; Photolabeling 
1. INTRODUCTION 
Besides their classical actions in the central ner- 
vous system, some BZDs interact with a second 
type of receptor which is mainly present in 
peripheral organs [l-4]. These peripheral-type 
BZD-binding sites can be selectively labeled either 
with a BZD derivative RoS-4864 [5] or with an iso- 
quinoline carboxamide derivative PKl 1195 [6]. 
Although insight into the physiological function 
of peripheral-type BZD receptors has recently 
emerged from several experimental approaches 
[7-91, the role of these receptors remains unclear. 
One approach to elucidating the molecular basis of 
the functional activity of the peripheral-type BZD 
receptors is to identify and purify them in order to 
clone and express these proteins. 
It is the aim of this paper to describe a 
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peripheral-type BZD-binding site present in the 
mitochondria of a cell easily cultured on a large 
scale, i.e. the CHO cell, and the purification and 
partial characterization of the putative binding 
protein with the aid of a nitrophenyl derivative of 
PK11195, the photoaffinity ligand [3H]PK14105 
previously described [lo], that also binds with high 
affinity to the BZD-binding site present in these 
cells. 
2. MATERIALS AND METHODS 
2.1. Preparation of the CHO cell mitochondrial fraction 
The CHO cells [ll] were cultured as described [12]. The cell 
layer was washed with PBS (65 mM NasHPOd, 1.46 mM 
KH2P04, 140 mM KCI, 140 mM NaCl) and incubated with 
0.12% trypsin for 5 min at 37°C; the cells were removed from 
the roller bottles and trypsin was neutralized with 5% fetal calf 
serum. The cell suspension was centrifuged for 5 min at 500 x 
g and the pellet was washed 3 times with PBS at 37°C and final- 
ly suspended in 2 mM Hepes, 70 mM sucrose, 210 mM D- 
mannitol, 1 mM EDTA, 0.3 mM PMSF, pH 7.4, ice-cold buf- 
fer. Typically, 1.2 x 10’ cells (0.3 g of protein) were 
homogenized in a glass homogenizer and then the mitochon- 
238 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 0 1989 Federation of European Biochemical Societies 
Volume 245, number 1,2 FEBS LETTERS March 1989 
drial fraction was prepared as described by Anholt et al. [13]. 
Briefly, the homogenate was centrifuged 15 min at 650 x g at 
4°C the supernatant was centrifuged 15 min at 6500 x g at 4°C 
and the resulting pellet was, 3 times, resuspended in 2 mM 
Hepes, 70 mM sucrose, 210 mM D-mannitol, 1 mM EDTA, 
0.3 mM PMSF, pH 7.4, buffer and centrifuged for 10 min at 
10000 x g to obtain the mitochondrial preparation (25 mg of 
protein) that was stored at -20°C until used. 
2.2. Binding of [3H]PKll195 and rHlPK14105 to the CHO 
mitochondrial preparation 
The mitochondrial preparation was washed and suspended in 
25 mM Tris-HCl buffer, pH 7.4, at a final concentration of 
1OOpg of protein per ml. For the saturation experiments, the 
mitochondria were incubated with appropriate amounts of 
[3H]PKl 1195 (66.0 Ci.mmol-‘, CEA, Gif-sur-Yvette, France) 
or [3H]PK14105 (87.0 Ci.mmol-‘, CEA) for 1 h in the absence 
or presence of 500 times excess of unlabeled PKll195 (Sanofi). 
For the determination of the displacement potencies of 
PKll195, Ro5-4864 (Sanofi), diazepam (Sigma), flunitrazepam 
(Sigma), and clonazepam (Sigma), the mitochondrial prepara- 
tion was incubated in the presence of [3H]PKl 1195 (5 nM) with 
various concentrations of unlabeled drugs. In both cases, 
saturation and displacement, he experiments were performed 
on 0.26 ml aliquots of the prepared mitochondrial suspension 
in 96-well flat-bottomed microtiter plates at 4°C in a final 
volume of 0.3 ml, and the incubations were terminated by 
filtration under vacuum through GF/C glass fiber filters (What- 
man) which had been previously soaked in 25 mM Tris-HCl 
buffer, pH 7.4, containing 0.1% Triton X-100 and 0.1% bovine 
serum albumin. The filters were washed three times with ice- 
cold buffer, dried, and placed in 6 ml of Ready Safe liquid scin- 
tillation cocktail (Beckman), then the radioactivity was deter- 
mined by liquid scintillation spectrometry. All values are 
expressed as specific binding obtained by the difference between 
the binding in the absence and presence of unlabeled PKll195. 
The triplicate determinations usually showed a variation of less 
than 10%. 
2.3. Photolabeling of the BZD-binding sites with fH]PK14105 
Photoaffinity labeling of the CHO mitochondrial BZD- 
binding sites was performed using [‘H]PKl4105, essentially as 
described by Doble et al. [lo]. Briefly, the mitochondrial 
preparation was washed 3 times with 5 mM Tris-HCl buffer, 
pH 7.4, containing 1 mM MgClz, 0.3 mM PMSF, 1 mM 
EDTA, 0.25 M sucrose, and resuspended in the same buffer at 
0.4 mg of protein per ml. Aliquots of 0.25 ml were placed in 
1.7 cm* cell culture dishes, [‘H]PKl4105 was added to a final 
concentration of 100 nM, and samples were then irradiated at 
4°C using an ultraviolet lamp (Model TF-35 L, Bioblock Scien- 
tific). In some experiments [‘H]PKl4105 was preincubated with 
the mitochondria in the dark before ultraviolet irradiation. As 
controls, samples were incubated either with [3H]PK14105 but 
not irradiated, or with [3H]PK14105 in the presence of a 500 
times excess of PKll195 during the irradiation. After the 
photolabeling, which was performed for times ranging from 10 
to 120 min, the mitochondrial preparation was extensively 
washed with 50 mM Tris-HCl buffer, pH 7.4, containing 
10 mM MgClz, 0.3 mM PMSF, 1 mM EDTA and subjected to 
SDS-PAGE followed by autoradiography, or used as a tracer 
for the purification as described below. 
2.4. Purification of a putative mitochondrial CHO BDZ 
peripheral binding site 
A fraction of freshly prepared CHO cell mitochondria 
(1OOpg of protein) was photolabeled with [3H]PK14105 by 
ultraviolet irradiation for 15 min at 4°C and, after extensive 
washing, added to unlabeled mitochondria (20 mg of protein). 
The mitochondrial preparation was resuspended in 2 mM 
Hepes, 70 mM sucrose, 210 mM D-mannitol, 1 mM EDTA, 
0.3 mM PMSF, pH 7.4, buffer at a protein concentration f 
2 mg . ml-‘, then extracted with digitonin (5 mg per mg protein) 
for 60 min at 4°C. The samples were then centrifuged at 
15000 x g, the pellet was washed with the same buffer as 
described above, and then the supernatants were pooled. The 
clear pooled supernatant was concentrated to 2 ml in a Cen- 
tricon 30 (Amicon) by centrifugation at 5000 x g at 4°C and 
loaded on a S300 Sephacryl (Pharmacia) gel filtration column 
(1.5 x 90 cm) equilibrated at 0.5 ml*min-’ in 5 mM Tris-HCl 
buffer, pH 7.4, containing 1 mM EDTA, 0.3 mM PMSF, 0.1% 
Triton X-100. Eluting material was monitored at 278 nm and 
2 ml fractions were collected. An aliquot of each fraction was 
used for radioactivity counting in a Beckman scintillation 
counter. The fractions containing radioactivity were pooled and 
applied to a radial compression separation system (Z Module, 
Waters Associates) equipped with a phenyl-FBondapack col- 
umn (10 pm, 2.0 x 10.0 cm, Radial-PAK, Waters Associates). 
The column was washed with 0.1% trifluoroacetic acid (TFA) 
and then a gradient from 5 to 95% of acetonitrile, 0.1% TFA 
was applied in 60 min. The flow rate was 1 .O ml. min-‘. 1 .O ml 
fractions were collected and an aliquot of each was used for 
counting the radioactivity. A fraction eluting at 53% 
acetonitrile was diluted to 30% acetonitrile with 0.1% TFA and 
chromatographed on a BU 300 reverse-phase column (2.1 x 
100 mm, Brownlee) using a gradient from 40 to 70% 
acetonitrile, 0.1% TFA, in 20 min, at 0.3 ml .min-‘. A main 
peak detected at 220 nm and containing more than 60% of the 
radioactivity injected was used for further analysis. 
2.5. SDS-PAGE, amino acid and NHz-terminal sequence 
analysis 
Aliquots of the purified ‘H-labeled binding site or the freshly 
labeled CHO mitochondria were subjected to SDS-PAGE [14]. 
After electrophoresis the gel was either soaked in the 
fluorographic reagent Amplify (Amersham) and auto- 
radiographed using Hyperfilm-MP (Amersham), or silver- 
stained with a kit available from Bio Rad. 
For amino acid analysis, the purified samples were dried in 
borosilicate tubes, hydrolysed with gaseous HCl at 160°C for 
1 h, derivatized to PTC-amino acids on a 420A Derivatizer (Ap- 
plied Biosystems Inc.), and then analysed on a 12OA separation 
system (Applied Biosystems Inc.) using the standard programs. 
For NHz-terminal sequencing, the purified 3H-photolabeled 
putative BZD-binding site was directly loaded onto a polybrene- 
coated filter and automatically sequenced with a gas-phase pro- 
tein sequencer (model 470A, Applied Biosystems Inc.) equipped 
with a 120A on-line PTH-amino acid analyser (Applied 
Biosystems Inc.). 
For amino acid analysis and sequencing of the proteins 
isolated by SDS-PAGE, the SDS gel was equilibrated for 3 min 
in 10 mM Caps buffer, pH 11 .O, 10% ethanol, and electroblot- 
ted onto a PVDF membrane (Millipore) as described [15]. The 
membrane was either colored with Ponceau S [16] or dried and 
239 
Volume 245, number 1,2 FEBS LETTERS March 1989 
subjected to autoradiography using Hyperfilm-‘H. In both 
cases the part of the PVDF membrane containing the 17 kDa 
band was cut into several small pieces and either subjected to 
amino acid analysis after vapor-phase hydrolysis as described 
above, or deposited on a polybrene-coated filter and 
automatically sequenced. 
3. RESULTS 
3.1. Binding of fH]PK11195 to the CHO 
mitochondrial preparation 
Binding of [3H]PK1 1195 to the crude mitochon- 
drial preparation was detected at a very low con- 
centration of ligand and was linear with increasing 
amounts of mitochondria in the range studied 
(lo-500,ug of protein per tube). At less than 
saturating concentrations, more than 95% of the 
total binding was specific. When the binding of 
[3H]PK1 1195 was determined at increasing concen- 
trations, a plateau was reached. The linear regres- 
sion analysis of the Scatchard plot showed a single 
component site with a Kd value of 12.0 + 1.0 nM 
and a maximal binding capacity of 23.0 + 
3 .O pmol/mg protein (fig. 1). The pharmacological 
properties of the peripheral-type BZD-binding site 
present in the CHO cells were evaluated in 
displacement experiments of [3H]PK1 1195 with 
cold PK11195, RoS-4864, diazepam, flunitra- 
zepam, and clonazepam. The results, shown in 
table 1, indicate the following order of potency: 
PKll195 > Ro5-4864 > diazepam = flunitrazepam 
% clonazepam . 
3.2. Photolabeling of the mitochondrial BZD- 
binding sites with ~HjPKl410.5 
The [3H]PK14105 photoaffinity ligand binds to 
the mitochondrial peripheral-type BZD-binding 
sites in a saturable manner. The linear regression 
analysis of the Scatchard plot showed a single com- 
ponent site with a Kd value of 28.0 + 3.0 nM and 
a maximal binding capacity of 21.0 f 
3.0 pmol/mg protein (fig. 1). Photoaffinity label- 
ing of the peripheral-type BZD-binding sites was 
performed, with or without preincubation in the 
dark of the mitochondrial preparation, with 
saturating concentrations of [3H]PK14105 before 
ultraviolet irradiation. After irradiation, perform- 
ed for different periods of time ranging from 10 to 
120 min, the mitochondrial preparation was exten- 
sively washed and subjected to SDS-PAGE 
analysis followed by autoradiography. Typically, 
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Fig. 1. Saturation and Scatchard plots of [3H]PKl 1195 (0) and 
[‘H]PKl4105 (0) binding to the CHO cell mitochondrial 
preparation. 
50-70070 of the specific [3H]PK14105 binding in 
the dark was irreversible after either 10 or 120 min 
of irradiation. The results shown in fig.2 indicated 
that a protein with an electrophoretical mobility 
corresponding to 17 kDa was labeled whether or 
not a preincubation in the dark was performed 
(lines 1 and 2). With increasing irradiation times, 
the 17 kDa band did not change, but several new 
minor bands were labeled (lines 3 and 4). The 
labeling of the main 17 kDa protein, as well as the 
minor ones, could be completely blocked by coin- 
cubation of the mitochondria with PK11195 dur- 
ing the irradiation (line 5). In the absence of 
irradiation, almost no radioactive bands were 
observed (line 6). 
3.3. Purification and chemical analysis of a 
putative BZD-binding site 
Freshly prepared CHO cell mitochondria 
(100 ,ug of protein) were photolabeled with 
Table 1 
Potency of several drugs in displacing [‘H]PKl1195 binding 
from the CHO mitochondrial-binding sites 
Drug ICJoa Relative potency 
PK11195 
Ro5-4864 
Diazepam 
Flunitrazepam 
Clonazepam 
3.2 x 10-s M 100 
7.9 x lo-’ M 4 
1.6 x 1O-5 M 0.2 
2.0 x lO-5 M 0.2 
>l.O x lO-4 M <O.Ol 
a 50% binding inhibiting concentration 
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Fig.2 Autoradiograms of SDS-PAGE analysis of [3H]PK14105 photolabeled CHO mitochondrial preparation. Lanes: 1 and 7, 
molecular mass standards; 2, membranes preincubated for 1 h in the dark at 4°C with [3H]PK14105 and then UV irradiated for 10 min; 
3, membranes incubated with [‘H]PKl4105 and UV irradiated for 90 min; 4, membranes incubated with [‘H]PKl4105 and UV 
irradiated for 120 min; 5, membranes incubated with [3H]PK14105 in the presence of 10e6 M PKI 1195 and UV irradiated for 90 min; 
6, membranes incubated with [3H]PK14105 for 90 min but not UV irradiated. 
[3H1PK14105 and added to unlabeled mitochon- the material eluting in this peak showed a major 
dria (20 mg of protein). The preparation was then band of 17 kDa and several minor bands with 
extracted with digitonin, concentrated, and loaded lower and higher molecular masses. These minor 
on a gel-filtration column. A main peak, contain- contaminants were eliminated by a second HPLC 
ing more than 90% of the loaded radioactivity, step on a butyl reverse-phase column, The material 
was found between the elution positions of bovine eluting with the single radioactive peak at 17 min 
serum albumin and human growth hormone; the (fig.3C), showed on silver-stained SDS-PAGE a 
rest of the radioactivity eluted in the dead volume single 17 kDa band that co-migrated with the 
of the column (fig.3A). The radioactive fractions radiolabeled protein (fig.4). The amino acid com- 
of the main peak were pooled and chromatograph- position of the HPLC purified material and the 
ed on a phenyl reverse-phase HPLC column. 17 kDa protein electroblotted from SDS-PAGE 
Radioactivity determination of the collected frac- are shown in table 2. NHz-terminal sequence 
tions showed three main peaks (fig.3B). SDS- analysis of either the purified material, or the 
PAGE followed by autoradiography indicated that 17 kDa band electroblotted from SDS-PAGE onto 
the 17 kDa protein was present in the peak eluting a PVDF membrane, usually failed to give a se- 
at 40 min. Silver-stained SDS-PAGE analysis of quence. In two out of six purifications, however, 
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Fig.3. Purification of the 17 kDa putative peripheral BDZ- 
binding site from the photolabeled CHO mitochondrial 
preparation. Typical elution profile from: (A) gel-filtration 
chromatography (molecular mass markers are 1, blue dextran 
2000 (2 x 106); 2, bovine serum albumin (6.7 x 104); 3, human 
growth hormone (2.2 x 104); and 4, tryptophan (2.0 x 10’); (B) 
reverse-phase HPLC on phenyl+Bondapack column; (C) 
reverse-phase HPLC on C4 Brownlee column. 
a single sequence was detected, but the initial yields 
in both cases were very low, 3-6070 (calculated 
from the amino acid analysis of the material 
deposited on the filter). This sequence was Ala- 
Pro-Ser-X-Val-Pro-Ala-Val-Gly-Leu. The repeti- 
tive yields, calculated from the linear regression 
analysis of the amount of PTH-amino acids re- 
covered after each degradation cycle, were 
88-90%. These sequencing experiments suggest 
Fig.4. SDS-PAGE of the purified photolabeled 17 kDa putative 
peripheral BDZ-binding site. The same sample was loaded in 
parallel lanes of a gel and then either silver-stained (A) or sliced 
and used for tritium localization (B). The arrows correspond to 
the following molecular mass markers: 1, ovalbumin (46.0 x 
10’); 2, carbonic anhydrase (30.0 x 10’); 3, trypsin inhibitor 
(21.5 x 10’); and 4, lysozyme (14.3 x 10’). 
that the purified protein has the N-terminal block- 
ed, and that the sequence obtained may cor- 
respond to an internal sequence of the putative 
BZD-binding site resulting from N-terminal 
degradation of the protein during purification. 
The presence of a contaminating protein with a se- 
quenceable N-terminal that co-purified with this 
protein cannot be excluded. 
Table 2 
Amino acid composition of the purified putative 
benzodiazepine-binding site 
Amino acid HPLC purified 
protein” 
Blotted 
protein” 
Asx 
Glx 
Ser 
GlY 
His 
Arg 
Thr 
Ala 
Pro 
Tyr 
Val 
Met 
Ile 
Leu 
Phe 
Lys 
7.5 + 0.7 
9.0 * 1.4 
12.7 * 0.6 
17.2 + 1.3 
5.3 * 0.2 
13.5 * 1.0 
9.2 + 1.6 
16.3 + 0.6 
12.0 + 1.0 
8.3 & 0.6 
6.0 t 0.5 
1.5 + 0.5 
2.0 t 0.3 
16.7 + 4.0 
5.7 f 0.6 
3.7 f 0.6 
9.0 f 1.0 
11.5 * 3.5 
6.5 * 0.6 
15.5 + 0.7 
2.0 * 1.0 
9.0 * 1.0 
9.5 * 2.1 
21.0 * 0.7 
15.5 + 0.7 
9.5 f 0.7 
10.0 + 1.4 
3.0 + 1.4 
2.5 + 0.7 
23.5 k 3.5 
6.0 + 1.5 
2.0 * 1.4 
a The values are the mean of triplicate determinations and the 
compositions are calculated for a 17-18 kDa protein. Cys 
and Trp are not determined 
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4. DISCUSSION 
The isoquinoline carboxamide derivative 
[3H]PK1 1195, a selective ligand for the peripheral- 
type BZD-binding site, binds to CHO cell 
mitochondria in a specific and saturable manner 
with an apparent Kd of 12.0 * 1.0 nM and a max- 
imal binding capacity of 23.0 + 2.0 pmol/mg pro- 
tein. This receptor density is similar to the one 
described for the rat testis and lung mitochondria 
(25-35 pmol/mg protein) [3,4,19,20], two of the 
tissues, together with the adrenal gland 
(90-120 pmol/mg protein), for which the highest 
density of binding sites has been reported 
[3,4,17,20]. The pharmacological characterization 
of this CHO BZD-binding site, based on the 
displacement of [3H]PK11195 by several drugs of 
known binding specificity, indicated that it is of 
the peripheral-type [l-4,17]. 
We extended the characterization of the CHO 
mitochondria-binding site with the use of another 
isoquinoline carboxamide compound, [3H]PK- 
14105, a molecule whose pharmacological profile 
is nearly identical to that of PK11195 [lo-191. 
PK14105 is a nitrophenyl derivative of PK11195 
that can be covalently incorporated into the BZD- 
binding site when exposed to ultraviolet light [lo]. 
[3H]PK14105 binds with high affinity to the CHO 
mitochondrial preparation and, in our experimen- 
tal conditions, 50-70% of the specific binding in 
the dark was irreversible after irradiation. When 
the mitochondria were incubated with the photoaf- 
finity probe and irradiated for 10 min, a 17 kDa 
protein was predominantly labeled providing fur- 
ther evidence for the identification of the CHO- 
binding site with those previously described 
[10,18-201. However, with longer irradiation 
times several other proteins were labeled, the most 
important of which were in the 31-35 kDa range. 
Whether or not these proteins are associated with 
the 30 kDa protein or with the voltage-dependent 
anion channel, labeled with [3H]flunitrazepam in 
rat kidney mitochondria, described by Snyder et 
al. [21] is currently being studied in our laboratory. 
In conclusion, these labeling experiments howed 
that the 17 kDa protein is the main binding site of 
[3H]PK14105, but also that other proteins can be 
part of, or be associated with the BZD receptor 
present in the CHO cells. 
Since the BZD-binding sites are abundant in the 
CHO mitochondria, we used these cells as the star- 
ting material for the purification of the main 
binding protein. Using the photolabeled material 
as tracer, a 17 kDa protein was purified from 
digitonin-solubilized CHO mitochondria by gel- 
filtration chromatography and two reverse-phase 
HPLC steps. The purified material showed a single 
band on silver-stained SDS gels that corresponded 
to the only band detected by radioautography of 
the same gel. Analysis of the purified protein in 
several different chromatographic systems failed 
to separate the 17 kDa protein from the radioac- 
tivity (data not shown), strongly suggesting identi- 
ty of the silver-stained and radioactive material. 
The amino acid analysis of the HPLC purified pro- 
tein and of the 17 kDa protein electroblotted after 
SDS-PAGE are similar and within the expected 
variability when working in the low picomolar 
range. Minor differences in His, Pro and Val con- 
tents may reflect the presence of residual con- 
taminants in the HPLC purified material that, in 
some preparations, were detected in SDS-PAGE. 
Attempts to sequence the N-terminal of the 17 kDa 
protein usually failed. However, in some batches a 
sequence was obtained that did not show any 
homology when compared to the sequences present 
in the GenBank data bank. The lack of an N- 
terminal sequence and, when observed, the very 
low initial yield in the sequencing experiments ug- 
gest that the N-terminal of the purified protein is 
blocked, and that the sequence obtained may cor- 
respond either to an internal sequence of the BZD- 
binding site resulting from N-terminal degradation 
of the protein during the purification, or to a non- 
blocked contaminant protein that co-purified with 
this protein. Work is in progress in our laboratory 
to obtain, purify, and sequence peptides from this 
protein, as well as to determine whether or not the 
labeled protein is the functional BZD receptor. 
In conclusion, we described a peripheral-type 
BZD-binding site in CHO cells, and the purifica- 
tion and partial characterization of a putative 
17 kDa binding protein from the mitochondria of 
these cells. Since CHO cells have a high density of 
binding sites and are easily cultured on a large 
scale, they provide an interesting source for this 
receptor which may facilitate its complete 
characterization and lead to the cloning of the 
gene. 
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